



MS 122
K. W. Batchelor
4/1/96

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: K. W. Batchelor, et al.
Filed: March 16, 1995
Serial No.: 08/405,120
For: ANDROSTENONE DERIVATIVE

Art Unit: 1202
Examiner: D. Daus

Assistant Commissioner of Patents and Trademarks
Washington, DC. 20231

AMENDMENT AND RESPONSE

Sir:

This is in response to the Office Action mailed November 24, 1995.

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 1, line 3, in front of "PCT application" insert -- pending --.

Page 1, line 4, delete "16/09/94" and substitute therefor --September 16, 1994--.

Page 1, line 4, after "Glaxo Inc." insert -- which is a continuation-in-part of USSN 08/123,280 filed September 17, 1993 and now abandoned--.

Page 7, in formula (VII), delete "CO₂X" and substitute therefor --COX--.

IN THE CLAIMS:

Please amend the claims as follows:

Claim 3, line 2, delete "disease" and substitute therefor --condition--.

Claim 8. (Amended) A method of treating an androgen responsive or mediated condition [disease] in a mammal suffering from said condition [disease] comprising administering to said mammal a safe and effective [androgen responsive or mediated disease] amount of the compound of Claim 1.

Claim 9, line 1, delete "disease" and substitute therefor --condition--.

Claim 11. (Amended) A method of treating an androgen responsive or mediated condition [disease] in a mammal suffering from said condition

A'
Q2
G3
23